PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290857
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1290857
Immune Repertoire Sequencing Market size was valued at USD 1,315.8 million in 2022, expanding at a CAGR of 7.7% from 2023 to 2030.
Immune repertoire sequencing is a technique used to analyze the diversity and composition of the immune system's repertoire of antibodies or T cell receptors. Immune repertoire refers to all of the unique T-cell receptor and B-cell receptor genetic rearrangements within the adaptive immune system It has unique advantages compared to the more common diagnostic and prognostic techniques that predate it. The traditional strategies for studying the immune repertoire, which include spectating, Sanger sequencing et al., are laborious, costly, and insufficient for generating a high-resolution picture of the immune repertoire. For instance, specific disease prognoses can lead to the evolution of similar or identical CDR3s in different patients. CDR3 sequencing can thus potentially be used for diagnosis.
Immune repertoire sequencing can accessory pharmacogenomics by providing additional acumens into a patient's immune system and its response to drug therapies. For example, in the perspective of cancer treatment, immune repertoire sequencing can help identify tumor-specific antigens recognized by the immune system. However, the increase in demand for immunotherapy for cancer and other infectious diseases is expected to propel the growth of the Immune Repertoire Sequencing Market. Immunotherapy drugs work better in some cancers than others and while they can be a miracle for some, they fail to work for all patients. Overall response rates are about 15 to 20%. And also there is so much pharmaceutical R&D that cancer immunotherapy has its own stock index of 25 companies worth USD100 million or more, according to Johns Hopkins Medicine.
The Global Immune Repertoire Sequencing Market is segmented on the basis of Product Type, Application, Technology, and Region.
The market is divided into three categories based on product type: Instruments and Assay Kits. Assay Kits are likely to dominate the market. These kits typically include reagents and protocols for sample preparation, library construction, sequencing, and data analysis.
The market is divided into six categories based on application: Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection, and Tolerance, Infectious Diseases, and Others. Cancer Immunotherapy dominates the market and is likely to maintain its dominance during the forecast period. Cancer immunotherapy is a rapidly advancing field that utilizes the body's immune system to fight cancer.
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Immune Repertoire Sequencing Market, due to rising Government Funding to Improve the Healthcare Infrastructure. Medical and Health Research and Development predicted that the Federal government investment accounts for one-quarter (25%) of all U.S. medical and health R&D at USD61.5 billion, with the National Institutes of Health (NIH) alone accounting for 20% (USD48.9 billion) of all such investment in 2020. At this level, NIH is the second largest funder of medical and health research after the biopharmaceutical industry. However, Increased government funding can provide researchers and institutions with more resources to conduct research on immune repertoire sequencing. Europe and the Asia Pacific are expected to expand significant growth during the forecast period, due to increasing research and development and launches of novel products.
The demand for immune repertoire sequencing has been steadily increasing due to its vital role in understanding the immune system, disease progression, and developing personalized therapies. The companies provide sequencing instruments, reagents, and software solutions for immune repertoire analysis. The immune repertoire sequencing market is competitive, with a range of companies and research institutions driving innovation and providing solutions for sequencing and analyzing immune repertoires. Advancements in sequencing technologies, bioinformatics tools, and data analysis methods continue to shape the competitive landscape and contribute to the growth of the market. For example, in 2023, Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T-cells and B-cells, which play a key role in the immune response system.
Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next-generation sequencing of the adaptive immune system to advance Pfizer's growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.
The scope of this report covers the market by its major segments, which include as follows: